Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Indications for and complications of renal biopsy

INTRODUCTION

A percutaneous renal biopsy may be obtained for a number of reasons, including establishment of the exact diagnosis, as an aid to determine the nature of recommended therapy or to help decide when treatment is futile, and to ascertain the degree of active (ie, potentially reversible) and chronic (ie, irreversible) changes [1,2]. The degree of active or chronic changes helps determine prognosis and likelihood of response to treatment. In addition, kidney biopsy can be performed to help assess genetic diseases.

It is important to recognize that prognostication based upon renal pathology alone may be affected by the sample size (particularly in lesions that are focal in nature) and may not be very accurate in biopsies with few glomeruli (ie, ≤5). The findings in renal biopsy always need to be interpreted in the context of the clinical and laboratory features. Chronic changes (interstitial fibrosis and tubular atrophy), for example, are a sign of the magnitude and duration of prior injury.

The following topic review provides an overview of issues relating to percutaneous renal biopsy. Nonpercutaneous renal biopsy techniques are also discussed.

OVERVIEW

The routine evaluation of a percutaneous renal biopsy involves examination of the tissue under light, immunofluorescence (and immunoperoxidase in some laboratories [3]), and electron microscopy. Each component of the evaluation can provide important diagnostic information. (See appropriate topic reviews for discussions concerning pathologic findings in individual disorders.) The routine immunofluorescence examination of biopsy specimens should include (at a minimum) evaluation of IgG, IgM, IgA, C3, C1q, albumin, fibrin, and kappa and lambda immunoglobulin light chains. Special studies, including evaluation of serum amyloid A deposits, IgG subclasses (IgG1-4), and collagen chains (alpha 3.4 and 5) may be helpful in some cases where available. (See "Thin basement membrane nephropathy (benign familial hematuria)" and "Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)".)

Justification for the routine application of electron microscopy comes largely from studies in the 1960s and 1970s, which showed that this technique provided substantive diagnostic information beyond that obtained from light microscopy in nearly 50 percent of cases. However, most of these studies were performed at a time when immunofluorescence microscopy was not widely available.

                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: Dec 31, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Madaio MP. Renal biopsy. Kidney Int 1990; 38:529.
  2. Appel GB. Renal biopsy: How effective, what technique, and how safe. J Nephrol 1993; 6:4.
  3. Mölne J, Breimer ME, Svalander CT. Immunoperoxidase versus immunofluorescence in the assessment of human renal biopsies. Am J Kidney Dis 2005; 45:674.
  4. Haas M. A reevaluation of routine electron microscopy in the examination of native renal biopsies. J Am Soc Nephrol 1997; 8:70.
  5. Richards NT, Darby S, Howie AJ, et al. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9:1255.
  6. Fuiano G, Mazza G, Comi N, et al. Current indications for renal biopsy: a questionnaire-based survey. Am J Kidney Dis 2000; 35:448.
  7. Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.
  8. Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant 2001; 16:1364.
  9. Pfister M, Jakob S, Frey FJ, et al. Judgment analysis in clinical nephrology. Am J Kidney Dis 1999; 34:569.
  10. Cohen AH, Nast CC, Adler SG, Kopple JD. Clinical utility of kidney biopsies in the diagnosis and management of renal disease. Am J Nephrol 1989; 9:309.
  11. McGregor DO, Lynn KL, Bailey RR, et al. Clinical audit of the use of renal biopsy in the management of isolated microscopic hematuria. Clin Nephrol 1998; 49:345.
  12. Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110:434.
  13. Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.
  14. Korbet SM. Percutaneous renal biopsy. Semin Nephrol 2002; 22:254.
  15. Mattix H, Singh AK. Is the bleeding time predictive of bleeding prior to a percutaneous renal biopsy? Curr Opin Nephrol Hypertens 1999; 8:715.
  16. Stiles KP, Hill C, LeBrun CJ, et al. The impact of bleeding times on major complication rates after percutaneous real-time ultrasound-guided renal biopsies. J Nephrol 2001; 14:275.
  17. Whittier WL, Korbet SM. Renal biopsy: update. Curr Opin Nephrol Hypertens 2004; 13:661.
  18. Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133:134.
  19. Lin WC, Yang Y, Wen YK, Chang CC. Outpatient versus inpatient renal biopsy: a retrospective study. Clin Nephrol 2006; 66:17.
  20. Nass K, O'Neill WC. Bedside renal biopsy: ultrasound guidance by the nephrologist. Am J Kidney Dis 1999; 34:955.
  21. Diaz-Buxo JA, Donadio JV Jr. Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. Clin Nephrol 1975; 4:223.
  22. Stratta P, Canavese C, Marengo M, et al. Risk management of renal biopsy: 1387 cases over 30 years in a single centre. Eur J Clin Invest 2007; 37:954.
  23. Waldo B, Korbet SM, Freimanis MG, Lewis EJ. The value of post-biopsy ultrasound in predicting complications after percutaneous renal biopsy of native kidneys. Nephrol Dial Transplant 2009; 24:2433.
  24. Manno C, Strippoli GF, Arnesano L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 2004; 66:1570.
  25. Berliner AR, Fine DM. There’s something fishy about this bleeding. NDT Plus 2011; 4:270.
  26. Clinical competence in percutaneous renal biopsy. Health and Public Policy Committee. American College of Physicians. Ann Intern Med 1988; 108:301.
  27. Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000; 35:433.
  28. Kohli HS, Jairam A, Bhat A, et al. Safety of kidney biopsy in elderly: a prospective study. Int Urol Nephrol 2006; 38:815.
  29. Uezono S, Hara S, Sato Y, et al. Renal biopsy in elderly patients: a clinicopathological analysis. Ren Fail 2006; 28:549.
  30. Moutzouris DA, Herlitz L, Appel GB, et al. Renal biopsy in the very elderly. Clin J Am Soc Nephrol 2009; 4:1073.
  31. Packham D, Fairley KF. Renal biopsy: indications and complications in pregnancy. Br J Obstet Gynaecol 1987; 94:935.
  32. Chen HH, Lin HC, Yeh JC, Chen CP. Renal biopsy in pregnancies complicated by undetermined renal disease. Acta Obstet Gynecol Scand 2001; 80:888.
  33. Kuller JA, D'Andrea NM, McMahon MJ. Renal biopsy and pregnancy. Am J Obstet Gynecol 2001; 184:1093.
  34. Lindheimer MD, Davison JM. Renal biopsy during pregnancy: 'to b . . . or not to b . . .?'. Br J Obstet Gynaecol 1987; 94:932.
  35. Day C, Hewins P, Hildebrand S, et al. The role of renal biopsy in women with kidney disease identified in pregnancy. Nephrol Dial Transplant 2008; 23:201.
  36. Shidham GB, Siddiqi N, Beres JA, et al. Clinical risk factors associated with bleeding after native kidney biopsy. Nephrology (Carlton) 2005; 10:305.
  37. Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol 2004; 15:142.
  38. Mendelssohn DC, Cole EH. Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys. Am J Kidney Dis 1995; 26:580.
  39. Schow DA, Vinson RK, Morrisseau PM. Percutaneous renal biopsy of the solitary kidney: a contraindication? J Urol 1992; 147:1235.
  40. Gesualdo L, Cormio L, Stallone G, et al. Percutaneous ultrasound-guided renal biopsy in supine antero-lateral position: a new approach for obese and non-obese patients. Nephrol Dial Transplant 2008; 23:971.
  41. Wiseman DA, Hawkins R, Numerow LM, Taub KJ. Percutaneous renal biopsy utilizing real time, ultrasonic guidance and a semiautomated biopsy device. Kidney Int 1990; 38:347.
  42. Maya ID, Maddela P, Barker J, Allon M. Percutaneous renal biopsy: comparison of blind and real-time ultrasound-guided technique. Semin Dial 2007; 20:355.
  43. Doyle AJ, Gregory MC, Terreros DA. Percutaneous native renal biopsy: comparison of a 1.2-mm spring-driven system with a traditional 2-mm hand-driven system. Am J Kidney Dis 1994; 23:498.
  44. Riehl J, Maigatter S, Kierdorf H, et al. Percutaneous renal biopsy: comparison of manual and automated puncture techniques with native and transplanted kidneys. Nephrol Dial Transplant 1994; 9:1568.
  45. Mahoney MC, Racadio JM, Merhar GL, First MR. Safety and efficacy of kidney transplant biopsy: Tru-Cut needle vs sonographically guided Biopty gun. AJR Am J Roentgenol 1993; 160:325.
  46. Kim D, Kim H, Shin G, et al. A randomized, prospective, comparative study of manual and automated renal biopsies. Am J Kidney Dis 1998; 32:426.
  47. Burstein DM, Korbet SM, Schwartz MM. The use of the automatic core biopsy system in percutaneous renal biopsies: a comparative study. Am J Kidney Dis 1993; 22:545.
  48. Feneberg R, Schaefer F, Zieger B, et al. Percutaneous renal biopsy in children: a 27-year experience. Nephron 1998; 79:438.
  49. Tøndel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol 2012; 7:1591.
  50. Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 2012; 60:62.
  51. Nicholson ML, Wheatley TJ, Doughman TM, et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int 2000; 58:390.
  52. Pasquariello A, Innocenti M, Batini V, et al. Theoretical calculation of optimal depth in the percutaneous native kidney biopsy to drastically reduce bleeding complications and sample inadequacy for histopathological diagnosis. Nephrol Dial Transplant 2007; 22:3516.
  53. Katopodis KP, Katsios CG, Koliousi EL, et al. Life-threatening hemorrhage from abdominal aorta following a percutaneous renal biopsy. Clin Nephrol 2006; 65:446.
  54. Eiro M, Katoh T, Watanabe T. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol 2005; 9:40.
  55. Soares SM, Fervenza FC, Lager DJ, et al. Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients. Am J Kidney Dis 2008; 52:1079.
  56. Fish R, Pinney J, Jain P, et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010; 5:1977.
  57. Manno C, Bonifati C, Torres DD, et al. Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis 2011; 57:850.
  58. Whittier WL. Percutaneous kidney biopsy: "the needle and the damage done"? Am J Kidney Dis 2011; 57:808.
  59. Harrison KL, Nghiem HV, Coldwell DM, Davis CL. Renal dysfunction due to an arteriovenous fistula in a transplant recipient. J Am Soc Nephrol 1994; 5:1300.
  60. McCune TR, Stone WJ, Breyer JA. Page kidney: case report and review of the literature. Am J Kidney Dis 1991; 18:593.
  61. Bakri RS, Prime M, Haydar A, et al. Three 'Pages' in a chapter of accidents. Nephrol Dial Transplant 2003; 18:1917.
  62. Patel TV, Goes N. Page kidney. Kidney Int 2007; 72:1562.
  63. Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years' experience. Clin Nephrol 1992; 38:135.
  64. Renal Physicians Association. RPA position on optimal length of observation after percutaneous renal biopsy. Clin Nephrol 2001; 56:179.
  65. Hergesell O, Felten H, Andrassy K, et al. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant 1998; 13:975.
  66. Khajehdehi P, Junaid SM, Salinas-Madrigal L, et al. Percutaneous renal biopsy in the 1990s: safety, value, and implications for early hospital discharge. Am J Kidney Dis 1999; 34:92.
  67. Chodak GW, Gill WB, Wald V, Spargo B. Diagnosis of renal parenchymal diseases by a modified open kidney biopsy technique. Kidney Int 1983; 24:804.
  68. Farrugia E, Larson TS. Open renal biopsy: Indications and complications (abstract). J Am Soc Nephrol 1992; 3:342.
  69. Conlon PJ, Kovalik E, Schwab SJ. Percutaneous renal biopsy of ventilated intensive care unit patients. Clin Nephrol 1995; 43:309.
  70. Gimenez LF, Micali S, Chen RN, et al. Laparoscopic renal biopsy. Kidney Int 1998; 54:525.
  71. Gupta M, Haluck RS, Yang HC, et al. Laparoscopic-assisted renal biopsy: an alternative to open approach. Am J Kidney Dis 2000; 36:636.
  72. Anas CM, Hattori R, Morita Y, et al. Efficiency of laparoscopic-assisted renal biopsy. Clin Nephrol 2008; 70:203.
  73. Mal F, Meyrier A, Callard P, et al. The diagnostic yield of transjugular renal biopsy. Experience in 200 cases. Kidney Int 1992; 41:445.
  74. Stiles KP, Yuan CM, Chung EM, et al. Renal biopsy in high-risk patients with medical diseases of the kidney. Am J Kidney Dis 2000; 36:419.
  75. Abbott KC, Musio FM, Chung EM, et al. Transjugular renal biopsy in high-risk patients: an American case series. BMC Nephrol 2002; 3:5.
  76. Meyrier A. Transjugular renal biopsy. Update on hepato-renal needlework. Nephrol Dial Transplant 2005; 20:1299.
  77. Cluzel P, Martinez F, Bellin MF, et al. Transjugular versus percutaneous renal biopsy for the diagnosis of parenchymal disease: comparison of sampling effectiveness and complications. Radiology 2000; 215:689.
  78. Thompson BC, Kingdon E, Johnston M, et al. Transjugular kidney biopsy. Am J Kidney Dis 2004; 43:651.
  79. Misra S, Gyamlani G, Swaminathan S, et al. Safety and diagnostic yield of transjugular renal biopsy. J Vasc Interv Radiol 2008; 19:546.
  80. Sam R, Leehey DJ, Picken MM, et al. Transjugular renal biopsy in patients with liver disease. Am J Kidney Dis 2001; 37:1144.
  81. Sam R, Ing TS. Transjugular renal biopsy: when to do it and when not to? Int J Artif Organs 2001; 24:595.
  82. Sam R, Chebrolu SB, Reyes CV, et al. Transjugular renal biopsy in an unconscious patient maintained on mechanical ventilation. Clin Nephrol 2003; 60:53.
  83. Fine DM, Arepally A, Hofmann LV, et al. Diagnostic utility and safety of transjugular kidney biopsy in the obese patient. Nephrol Dial Transplant 2004; 19:1798.
  84. Ahmed MS, Patel A, Borge MA, et al. Simultaneous transjugular renal biopsy and hemodialysis catheter placement in patients with ARF. Am J Kidney Dis 2004; 44:429.